Clinical trials: Cardiovascular Disease Acute
Aortic Dissection
A Real World Study on Fabulous® Thoracic Aortic Stent System for Stanford B Aortic Dissection
A multicenter, retrospective study to evaluate the real-world efficacy of the Fabulous thoracic aortic stent system in the treatment of Stanford Type B aortic dissection.
- Trial name
- NCT05965271
- Testing
- Fabulous Thoracic Aortic Stent System
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Hangzhou Endonom Medtech Co., Ltd.
Stroke, Acute Stroke
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke
- Trial name
- NCT07751328
- Testing
- Axana Scan and MRI
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wellumio R&D Australia Pty Ltd
Shock, Cardiogenic
A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack
Tilarginine Acetate Injection is a new type of drug that temporarily stops the body from making a bodily substance called nitric oxide. The body may produce excess nitric oxide following severe heart damage leading to shock.
- Trial name
- NCT00112281
- Testing
- Tilarginine Acetate Injection intravenous infusion
- Where
- 102 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- Arginox Pharmaceuticals
Acute Myocardial Infarction
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
- Trial name
- NCT00271765
- Testing
- INO-1001
- Where
- 16 sites in United States, Israel
- Volunteers
- 40 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Myocardial Infarction
Safety and Efficacy Study of MGuard Stent After a Heart Attack
The goal of this study is to demonstrate the superiority of the MGuard™ stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the…
- Trial name
- MASTER (NCT01368471)
- Testing
- MGuard, Control BMS or DES
- Where
- 7 sites in Poland, South Africa
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- InspireMD
Ischemic Stroke
Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke
Post-Market Registry on Use of Merci Retrieval System. Primary data to be collected will include: Post-procedure revascularization success 90-day mRS 0-2 90-day mortality
- Trial name
- NCT00478478
- Testing
- Mechanical Thrombectomy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Stryker Neurovascular
Acute Stroke, Transient Ischemic Attack
The Recurrence Study
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack (TIA) clinic.
- Trial name
- NCT03244215
- Testing
- Corneal Confocal Imaging, Magnetic resonance Imaging, Blood sample
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)
The objective of this study is to evaluate the efficacy and safety of the GENOSS SES in patients with acute coronary syndrome (ACS) in real-world pratice.
- Trial name
- GENOSS ACS (NCT06075368)
- Testing
- GENOSS Sirolimus Eluting Coronary Stent System
- Where
- South Korea
- Volunteers
- 757 people
- Sponsor
- Genoss Co., Ltd.
Liver Cirrhosis, Liver Failure
Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"
The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic patients with "acute-on-chronic liver failure".
- Trial name
- NCT01201720
- Testing
- Plasma exchange with albumin
- Where
- Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Instituto Grifols, S.A.
Chronic Kidney Disease, CKD
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who…
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Trial name
- ARTEMIS (NCT05746559)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 18 more
- Volunteers
- 555 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Ischemic Stroke
ReStore Thrombectomy Trial for Flow Restoration in Acute Ischemic Stroke Patients
The ReStore™ Thrombectomy device restores blood flow in the neurovascular by removing thrombus in patients experiencing ischemic stroke.
- Trial name
- NCT01437774
- Testing
- thrombectomy (ReStore or Merci)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Reverse Medical Corporation
Acute Ischemic Stroke
Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its…
- Trial name
- NCT05745311
- Testing
- The KPCXM18 injection
- Volunteers
- 240 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Acute Ischaemic Middle Cerebral Artery Stroke
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their…
- Trial name
- NCT01883011
- Testing
- Piracetam
- Where
- 44 sites in Argentina, Austria and 13 more
- Volunteers
- 571 people
- Sponsor
- UCB S.A. - Pharma Sector
Stroke
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more…
- Trial name
- GMAIS (NCT01221246)
- Testing
- GM602
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Heart Failure Acute
Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)
A feasibility study to investigate the safety and performance of the NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy System
- Trial name
- NCT03169803
- Testing
- NeuroTronik CANS Therapy™ System
- Where
- Panama
- Volunteers
- 40 people
- Sponsor
- NeuroTronik Inc.
Myocardial Infarction, Acute Coronary Syndromes
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
The purpose of this study is to determine whether the efficacy of tirofiban (a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v.
- Conditions
- Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina, Percutaneous Coronary Intervention
- Trial name
- ATLAST-PCI (NCT01245725)
- Testing
- Tirofiban (Aggrastat)
- Sponsor
- Medicure
Aortic Valve Disease, Ascending Aorta Abnormality
Valved Graft PMCF Study
Multicenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.
- Conditions
- Aortic Valve Disease, Ascending Aorta Abnormality, Aortic Dissection
- Trial name
- NCT04754217
- Testing
- VAVGJ, CAVGJ
- Where
- 25 sites in United States, Austria and 8 more
- Volunteers
- 260 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Acute Coronary Syndrome
FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes
The objective of this study is to evaluate the safety and efficacy of A 002 when added to high dose atorvastatin in subjects with an acute coronary syndrome (ACS)
- Trial name
- FRANCIS-ACS (NCT00743925)
- Testing
- Varespladib Methyl (A-002)
- Where
- 44 sites in Georgia, Russia and 1 more
- Volunteers
- 625 people
- Sponsor
- Anthera Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.